Woman battled breast cancer at the same time as her dog
Sara Page, 54, who lives in Cornwall, discovered she had an aggressive tumour in her left breast just months after being told her Border Collie-Labrador cross Freyja, aged nine, had incurable cancer.
Conclusions: This study is consistent with previous research showing that breast-conserving surgery after neoadjuvant chemotherapy does not reduce breast cancer–specific survival. In fact, patients undergoing breast-conservation after neoadjuvant therapy appeared to have better survival than patients undergoing mastectomy without radiation.
Conclusions: Breast cancer patients with germline BRCA1 mutations appear to have a shorter interval to brain progression while accounting for confounding factors.
Conclusions: This study showed no difference between Mebo and Biafine in the incidence and severity of breast skin dermatitis during radiation therapy. However, the use of Mebo ointment was associated with decreased severe pruritus and pain which could positively affect patient comfort and quality of life.
Response to "Male Patients With Breast Cancer: Addressing Needs Using an Educational Task Force". Clin J Oncol Nurs. 2018 Dec 01;22(6):610 Authors: Mahon SM, Nagtalon Cutrone J, Baron RH Abstract Male breast cancer is associated with hereditary risk for developing breast and other cancers. An estimated 4% of men with breast cancer have BRCA1 mutations, and 4%-16% have BRCA2 mutations. Men with a diagnosis of breast cancer have unique needs that need to be addressed in a caring and comprehensive manner. PMID: 30452015 [PubMed - in process]
This study was conducted to examine symptoms, symptom distress, cosmesis, QOL, and perceived body image in women during and after BCS with PBI. METHODS: A convenience sample of 31 women completed self-reports pre- and post-PBI over six months. Descriptive statistics and repeated- measures analysis were performed at baseline and three times post-PBI. FINDINGS: Most women reported satisfaction with body image and good QOL, despite a small decline in social well-being. Fatigue and mild to moderate symptom distress persisted over time. PMID: 30452011 [PubMed - in process]
Abstract The old adage "meeting of the minds" is always an exciting and motivating experience. I only wish that every healthcare provider could share this type of encounter in his or her professional career. Fortunately, I was lucky enough to meet Renee almost 20 years ago when we were both assigned to facilitate a metastatic breast cancer support group. Her role was the clinical social worker, and mine was to provide knowledge and education as the oncology educator. We were a fabulous team. PMID: 30452007 [PubMed - in process]
Abstract Heart failure and breast cancer have shared risks and morbidities. Multimodality therapies for breast cancer, including conventional chemotherapy, targeted therapeutics, radiation therapy, and hormonal agents, may make patients more susceptible to asymptomatic left ventricular dysfunction and clinical heart failure during and after treatment. New or preexisting left ventricular dysfunction may lead to interruptions in cancer treatment and limit options of breast cancer systemic therapy, leading to adverse outcomes. Early recognition and management of cardiovascular risk factors before, during, and after c...
Using qPCR, this study examined the utility of circulating cell-free DNA in auxiliary diagnosis, grading of malignant neoplasms, and prognostic prediction of breast cancer.Laboratory Medicine
Item response theory-based modeling places items on a unidimensional calibrated continuum which offers salient benefits for the efficient clinical integration of patient reported outcomes (PROs). The ability to screen for physical impairments related to cancer treatment using PROs offers the potential to address their chronic and damaging under treatment. However, lengthy screening tools are not feasible for repeated administration in saturated clinical workflows.
This study aimed to evaluate predictive value of 14 pro-angiogenic miRNAs for cardiotoxicity induced by epirubicin/cyclophosphamide follow by docetaxel (EC-D) in breast cancer (BC) patients. METHODS: Three hundred and sixty-three BC patients receiving EC-D neoadjuvant chemotherapy were consecutively enrolled in this prospective cohort study. Peripheral blood sample was obtained from each patient, and plasma was separated. The expressions of 14 pro-angiogenic miRNAs, cardiac troponin I (cTnI) and N-terminal pro brain natriuretic peptide (NT-proBNP) were evaluated. Left ventricular ejection fraction (LVEF) level at C0, t...